Ion Semiconductor Sequencing Data Presentations at AGBT Demonstrate More than >1,000-fold Throughput Scaling in First Two Years

Ion Semiconductor Sequencing Data Presentations at AGBT Demonstrate More than
       >1,000-fold Throughput Scaling in First Two Years on the Market

Performance scaling continues with the Ion Proton™ PI and PII chips in 2013

PR Newswire

CARLSBAD, Calif., Feb. 22, 2013

CARLSBAD, Calif., Feb. 22,2013 /PRNewswire/ --Life Technologies
Corporation(NASDAQ: LIFE) announced today that three scientists are
presenting data at the Advances in Genome Biology and Technology (AGBT)
conference showing the Ion PI chip is on the same rapid performance trajectory
demonstrated by the first three Ion PGM™chips. Since the first Ion chip
launched two years ago, semiconductor sequencing output has jumped over
1,000-fold from 10 Mb to more than 10 Gb, and that pace is expected to
continue in 2013.

  oDr. Jonathan M. Rothberg, Ion Torrent's Founder and CEO, presented data
    showing 16 Gb throughput on the Ion Proton™ Sequencer with readlengths out
    to 230 base pairs. Dr. Rothberg said he expects the Ion Proton™ PI Chip to
    deliver 12 Gb in customers' hands in the second quarter and 16 Gb by
  oJoseph Boland, Director of Research and Development, Cancer Genomics
    Research Laboratory, US National Cancer Institute, presented data showing
    his lab had generated greater than 12 Gb of high-quality data per run, out
    to 200 base pairread length,while sequencing a human exome on the Ion
    Proton™ Sequencer.
  oDr. Agnes Viale, manager of the Memorial Sloan Kettering Cancer Center's
    Genomics Core Laboratory, today will present transcriptome data showing
    her lab generated more than 80 million reads on a single run on the Ion
    Proton™ Sequencer.

"Ion semiconductor sequencing technology gets better, faster than any
sequencing technology," said Dr. Rothberg, who invented next-generation
sequencing nearly a decade ago. "We're seeing the same rapid ramp up in
performance on the Ion Proton™ PI chip that we saw on the three previous Ion
PGM™ chips, and we look forward to continuing that with the Ion PII chip."

About Life Technologies
Life Technologies Corporation(NASDAQ:LIFE) is a
global biotechnology company with customers in more than 160 countries using
its innovative solutions to solve some of today's most difficult scientific
challenges. Quality and innovation are accessible to every lab with its
reliable and easy-to-use solutions spanning the biological spectrum, with more
than 50,000 products for agricultural biotechnology, translational research,
molecular medicine and diagnostics, stem cell-based therapies, forensics, food
safety and animal health. Its systems, reagents and consumables represent some
of the most cited brands in scientific research including: Ion Torrent™,
Applied Biosystems®,Invitrogen™, Gibco®, Ambion®, Molecular Probes® and
Novex®.Life Technologiesemploys approximately 10,400 people and upholds its
ongoing commitment to innovation with more than 4,000 patents and exclusive
licenses. LIFE had sales of$3.8 billionin 2012. Visit us at our

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made by Life Technologies with the Securities and Exchange
Commission. Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.


Life Technologies Contact
Wes Conard

SOURCE Life Technologies

Press spacebar to pause and continue. Press esc to stop.